UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity

URLhttps://www.prnewswire.com/news-releases/ucb-annou
Sourceprnewswire.com
Date Published06/12/2025

Additional Reshoring Information:

Company/Division name UCB
Type of work Manufacturing
Reshoring category:Foreign Direct Investment
Total number of jobs (added or to be added):300
Year reshoring announced:2025
Domestically, the work will be done:In-house
Capital investment ($):5000
Country(ies) from which reshored:Belgium
If relevant, work nearshored to:-
Industry(ies):Chemicals
Product(s) reshoredbiopharma
What non-domestic negative factors made offshoring less attractive?Supply chain interruption
What domestic positive factors made reshoring more attractive?Impact on domestic economy, Skilled workforce availability/training
Find Reshoring Articles